Bristol-Myers Squibb (NY:BMY)

US Stocks Likely To Open Higher Ahead Of Amazon's Earnings: 'Buy The Dip' Mentality Remains Prevalent, Says Analyst ↗

February 06, 2025

U.S. stock futures rose on Thursday following Wednesday's advances as investors digest tariff pauses amid earnings reports.

Via Benzinga

Topics World Trade

Earnings Scheduled For February 6, 2025 ↗

February 06, 2025

Via Benzinga

Dow Rises Over 300 Points As Nvidia Surges: Investor Sentiment Improves, But Greed Index Remains In 'Fear' Zone ↗

February 06, 2025

Via Benzinga

Topics Stocks

Deep Dive Into Bristol-Myers Squibb Stock: Analyst Perspectives (9 Ratings) ↗

January 28, 2025

Via Benzinga

Decoding Bristol-Myers Squibb's Options Activity: What's the Big Picture? ↗

January 10, 2025

Via Benzinga

January 09, 2025

Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) will be reporting results tomorrow before the bell. Here’s what you need to know.

Bristol-Myers Squibb, Amazon And 3 Stocks To Watch Heading Into Thursday ↗

February 06, 2025

Via Benzinga

Earnings To Watch: Bristol-Myers Squibb (BMY) Reports Q4 Results Tomorrow

February 05, 2025

Via StockStory

McDonald's To $290? Here Are 10 Top Analyst Forecasts For Tuesday ↗

February 04, 2025

Via Benzinga

Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields ↗

February 04, 2025

Via Benzinga

Can Biotech Stocks Survive The Precarious Macro? ↗

February 03, 2025

We were having a nice rally in January 2025 until the reality of tariffs hit on Friday which killed the momentum developing off the mid-January lows.

Via Talk Markets

Topics Stocks / Equities World Trade

2 High-Yield Dividend Stocks to Hold Through 2025 and Beyond ↗

February 03, 2025

Goldman Sachs analyst Salveen Richter highlights potential benefits for biopharma from 340B reforms, while Medicaid cuts could pose risks for companies with significant drug exposure.

Is Big Pharma About To Win? Goldman Sachs Weighs In On 340B And Medicaid Shifts ↗

January 31, 2025

Via Benzinga

Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) as a First-Line Treatment Option for Adult Patients with Unresectable or Advanced Hepatocellular Carcinoma

January 31, 2025

Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma

January 31, 2025

3 Cheap Dividend Stocks That Pay More Than Double the S&P 500 Average ↗

January 29, 2025

The XLV bounced off the bottom this month up 4% to the $144 level led by biopharma and medtech.

Topics Stocks

Biotech And Healthcare Stocks Poised For Gains Ahead ↗

January 27, 2025

Via Talk Markets

Topics ETFs Stocks / Equities

10 Health Care Stocks With Whale Alerts In Today's Session ↗

January 27, 2025

Via Benzinga

Bristol Myers Squibb Presents Results from CheckMate -8HW Analysis Evaluating Opdivo® (nivolumab) plus Yervoy® (ipilimumab) Compared to Opdivo Monotherapy...

January 25, 2025

Cytokinetics Heart Drug's Future Sparks Optimism Despite M&A Hurdles and Royalty Deal Concerns: Analyst ↗

January 22, 2025

Cytokinetics receives a Buy rating from Stifel, with a promising outlook for aficamten in the $3 billion U.S. oHCM market, despite investor concerns over M&A and deals.

Via Benzinga

Deal Dispatch: Biden Punts TikTok Ban To Trump, Plus Another Legacy Retailer Goes Bankrupt ↗

January 17, 2025

Deal opportunities abound: KKR & Co.'s stake in Maya; DuPont's electronics business; Ingevity's North Charleston site; and S&W Seed Company.

Via Benzinga

Topics Government

Demand for Advanced Pancreatic Cancer Treatments at All Time High as Promising Options Come into Focus

January 22, 2025

From FN Media Group LLC

Via GlobeNewswire

January 17, 2025

HHS adds 15 drugs to Medicare Part D price negotiations, targeting cost reductions under the Inflation Reduction Act. New prices aim to save billions by 2027.

Via Benzinga

Topics Economy

Like Bristol-Myers Squibb And AbbVie, Johnson & Johnson Seeks To Bolster Neuropsychiatric Portfolio With $15 Billion Deal ↗

January 13, 2025

Johnson & Johnson's $14.6 billion acquisition of Intra-Cellular Therapies boosts its CNS portfolio with Caplyta and a promising clinical-stage pipeline.

Via Benzinga

ArsenalBio and Bristol Myers Squibb Achieve Milestone for AB-4000 Series as Part of Ongoing Multi-Program Collaboration to Advance Next-Generation T Cell Therapies for Solid Tumors

January 13, 2025

From Arsenal Biosciences

Via GlobeNewswire

Obesity Treatments, M&A Activity To Take Center Stage During Upcoming JPM Healthcare Conference ↗

January 09, 2025

JP Morgan highlights mixed sentiment for U.S. large-cap biopharma stocks as advancements in obesity drugs and key product launches shape 2025 outlook.

Via Benzinga

Alger Launches Russell Innovation ETF To Capitalize On Emerging Innovators ↗

January 08, 2025

Alger launched its INVN ETF, with holdings including BioMarin, Teradata, and Bristol-Myers Squibb.

Via Benzinga

Topics ETFs

Salesforce To Rally More Than 23%? Here Are 10 Top Analyst Forecasts For Wednesday ↗

January 08, 2025

Via Benzinga

3 High-Yield Dividend Stocks to Buy Now and Hold at Least a Decade ↗

January 04, 2025